Keros Therapeutics halts dosing of blood pressure treatment after safety review (updated)

Keros Therapeutics

12/12/2024 11:31

(Adds shares in paragraph 2, details from paragraph 3-5)
       Dec 12 (Reuters) - Keros Therapeutics  KROS.O  said on
Thursday that it has voluntarily halted usage of its 3.0
milligram (mg) and 4.5 mg doses of its high blood pressure
treatment in a mid-stage study based on a safety review.
    Shares of the company were down 67.2% at $22.49 in premarket
trading. 
    The company said it had halted dosing after observing
adverse events of fluid buildup around the heart in the trial. 
    Keros said it will work with the U.S. Food and Drug
Administration and other relevant regulatory authorities to
"address this as quickly as possible."
     The trial was testing the company's experimental drug
cibotercept, in combination with background therapy in patients
with pulmonary arterial hypertension-a type of high blood
pressure that affects the arteries in the lungs. 

 (Reporting by Sneha S K; Editing by Abinaya Vijayaraghavan)
 ((Sneha.SK@thomsonreuters.com;))